Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells

Oncotarget

Volumn 7, Issue 6, 2016, Pages 7297-7306

  Vujic, Igor ^a,b   Sanlorenzo, Martina ^a,c   Esteve Puig, Rosaura ^a   Vujic, Marin ^a,b   Kwong, Andrew ^a   Tsumura, Aaron ^a   Murphy, Ryan ^a   Moy, Adrian ^a   Posch, Christian ^b,d   Monshi, Babak ^b   Rappersberger, Klemens ^b   Ortiz Urda, Susana ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Universitatsklinik fur Dermatologie   (Austria)

^c UNIVERSITY OF TURIN   (Italy)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acyl protein thioesterase; APT 1; Melanoma; NRAS; Palmostatin B

Indexed keywords

ACYL PROTEIN THIOESTERASE 1; ACYL PROTEIN THIOESTERASE 2; ESTERASE INHIBITOR; ML 348; ML 349; PALMITOYL PROTEIN THIOESTERASE; PALMOSTATIN B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ENZYME INHIBITOR; GUANOSINE TRIPHOSPHATASE; LYPLA1 PROTEIN, HUMAN; LYPLA2 PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; PROPIOLACTONE; THIOL ESTER HYDROLASE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; MELANOMA CELL; MUTATIONAL ANALYSIS; ONCOGENE N RAS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; ENZYMOLOGY; GENETICS; MELANOMA; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; ENZYME INHIBITORS; GTP PHOSPHOHYDROLASES; HUMANS; MELANOMA; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; MUTATION; PROPIOLACTONE; RNA, SMALL INTERFERING; THIOLESTER HYDROLASES; TUMOR CELLS, CULTURED;

EID: 84981294741     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6907     Document Type: Article

References (43)

1. Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, Boscoe FP, Cronin KA, Lake A, Noone A-M, Henley SJ, Eheman CR, Anderson RN, et al. Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. J. Natl. Cancer Inst. 2015; 107: djv048.
2. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho K-H, Aiba S, Bröcker E-B, LeBoit PE, Pinkel D, Bastian BC. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 2005; 353: 2135-2147.
3. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat J-P, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, et al. A landscape of driver mutations in melanoma. Cell. 2012; 150: 251-263.
4. Lee J-H, Choi J-W, Kim Y-S. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br. J. Dermatol. 2011; 164: 776-784.
5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949-954.
6. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer. 2007; 7: 295-308.
7. Ekedahl H, Cirenajwis H, Harbst K, Carneiro A, Nielsen K, Olsson H, Lundgren L, Ingvar C, Jönsson G. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Br. J. Dermatol. 2013; 169: 1049-1055.
8. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011; 364: 2507-2516.
9. Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380: 358-365.
10. Thumar J, Shahbazian D, Aziz SA, Jilaveanu LB, Kluger HM. MEK targeting in N-RAS mutated metastatic melanoma. Mol. Cancer. 2014; 13: 45.
11. Jaiswal BS, Janakiraman V, Kljavin NM, Eastham-Anderson J, Cupp JE, Liang Y, Davis DP, Hoeflich KP, Seshagiri S. Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors. PLoS ONE. 2009; 4: e5717.
12. Vujic I, Sanlorenzo M, Posch C, Esteve-Puig R, Yen AJ, Kwong A, Tsumura A, Murphy R, Rappersberger K, Ortiz-Urda S. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget. 2015; 6: 969-78; doi: 10.18632/oncotarget.2824.
13. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc. Natl. Acad. Sci. 2013; 110: 4015-4020.
14. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2008; 26: 2139-2146.
15. Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Dummer R. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2012; 18: 555-567.
16. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VGR, Lebowitz PF, Le NT, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012; 13: 782-789.
17. Atefi M, Titz B, Avramis E, Ng C, Wong DJ, Lassen A, Cerniglia M, Escuin-Ordinas H, Foulad D, Comin-Anduix B, Graeber TG, Ribas A. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma. Mol. Cancer. 2015; 14: 27.
18. Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA,et al. Characteristics of Lung Cancers Harboring NRAS Mutations. Clin. Cancer Res. 2013; 19: 2584-2591.
19. Vujic I, Posch C, Sanlorenzo M, Yen AJ, Tsumura A, Kwong A, Feichtenschlager V, Lai K, Arneson DV, Rappersberger K, Ortiz-Urda SM. Mutant NRAS Q61 shares signaling similarities across various cancer types - potential implications for future therapies. Oncotarget. 2014; 5; 7936-44. doi: 10.18632/oncotarget.2326.
20. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989; 49: 4682-4689.
21. Shtivelman E, Davies MA, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE, Shtivelman E, Davies MA, Hwu P, Yang J, Lotem M, et al. Pathways and therapeutic targets in melanoma. Oncotarget. 2014; 5: 1701-1752. doi: 10.18632/oncotarget.1892.
22. Hancock JF, Magee AI, Childs JE, Marshall CJ. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell. 1989; 57: 1167-1177.
23. Hancock JF. Ras proteins: different signals from different locations. Nat. Rev. Mol. Cell Biol. 2003; 4: 373-384.
24. Rocks O, Peyker A, Kahms M, Verveer PJ, Koerner C, Lumbierres M, Kuhlmann J, Waldmann H, Wittinghofer A, Bastiaens PIH. An acylation cycle regulates localization and activity of palmitoylated Ras isoforms. Science. 2005; 307: 1746-1752.
25. Rusch M, Zimmermann TJ, Bürger M, Dekker FJ, Görmer K, Triola G, Brockmeyer A, Janning P, Böttcher T, Sieber SA, Vetter IR, Hedberg C, Waldmann H. Identification of Acyl Protein Thioesterases 1 and 2 as the Cellular Targets of the Ras-Signaling Modulators Palmostatin B and M. Angew. Chem. Int. Ed. 2011; 50: 9838-9842.
26. Xu J, Hedberg C, Dekker FJ, Li Q, Haigis KM, Hwang E, Waldmann H, Shannon K. Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. Blood. 2012; 119: 1032-1035.
27. Dekker FJ, Rocks O, Vartak N, Menninger S, Hedberg C, Balamurugan R, Wetzel S, Renner S, Gerauer M, Schölermann B, Rusch M, Kramer JW, Rauh D, et al. Small-molecule inhibition of APT1 affects Ras localization and signaling. Nat. Chem. Biol. 2010; 6: 449-456.
28. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483: 603-607.
29. Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She Q-B, Gallardo H, Liu C, Merghoub T, Hefter B, Dolgalev I, Viale A, Heguy A, et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF. Oncogene. 2012; 31: 446-457.
30. Moodie SA, Willumsen BM, Weber MJ, Wolfman A. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science. 1993; 260: 1658-1661.
31. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer. 2002; 2: 489-501.
32. Adibekian A, Martin BR, Chang JW, Hsu K-L, Tsuboi K, Bachovchin DA, Speers AE, Brown SJ, Spicer T, Fernandez-Vega V, Ferguson J, Cravatt BF, Hodder P, et al. Characterization of a Selective, Reversible Inhibitor of Lysophospholipase 1 (LYPLA1) [Internet]. In: Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD): National Center for Biotechnology Information (US); 2010 [cited 2014 Oct 22]. at http://www.ncbi.nlm.nih.gov/books/NBK189924/
33. Adibekian A, Martin BR, Chang JW, Hsu K-L, Tsuboi K, Bachovchin DA, Speers AE, Brown SJ, Spicer T, Fernandez-Vega V, Ferguson J, Cravatt BF, Hodder P, et al. Characterization of a Selective, Reversible Inhibitor of Lysophospholipase 2 (LYPLA2) [Internet]. In: Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD): National Center for Biotechnology Information (US); 2010 [cited 2015 Apr 23]. at http://www.ncbi.nlm.nih.gov/books/NBK189927/
34. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 2014; 13: 140-156.
35. De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin. Ther. Targets. 2012; 16: S17-S27.
36. Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PloS One. 2013; 8: e57289.
37. Gibbs JB, Oliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu. Rev. Pharmacol. Toxicol. 1997; 37: 143-166.
38. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001; 61: 131-137.
39. Gajewski TF, Salama AK, Niedzwiecki D, Johnson J, Linette G, Bucher C, Blaskovich MA, Sebti SM, Haluska F,$author.lastName $author firstName. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). J. Transl. Med. 2012; 10: 246.
40. Fedorenko IV, Gibney GT, Smalley KSM. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene. 2013; 32: 3009-3018.
41. Information NC for B, Pike USNL of MR, BethesdaMD, 20894USA. PubChem BioActivity Analysis: Data Table [Internet]. [cited 2015 Jun 9]; at http://pubchem.ncbi.nlm.nih.gov/assay/asis.cgi?reqid=1036661400607808426&q=r&version=1.2
42. Dekker FJ, Vartak N, Hedberg C. Development of Acyl Protein Thioesterase 1 (APT1) Inhibitor Palmostatin B That Revert Unregulated H/N-Ras Signaling [Internet]. In: Waldmann H, Janning P, editors. Concepts and Case Studies in Chemical Biology. Wiley-VCH Verlag GmbH & Co. KGaA; 2014 [cited 2014 Sep 18]. p. 123-140.at http://onlinelibrary.wiley.com/doi/10.1002/9783527687503.ch8/summary
43. Burd CE, Liu W, Huynh MV, Waqas MA, Gillahan JE, Clark KS, Fu K, Martin BL, Jeck WR, Souroullas GP, Darr DB, Zedek DC, Miley MJ, et al. Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Cancer Discov. 2014; 4: 1418-1429.